Genomic alterations co-occurred in the TP53 and STK11/LKB1 tumor suppressor genes, which define the unique biology, therapeutic sensitivities, and immune conditions of different subgroups of NSCLC with KRAS mutations (113). The gene discussed is STK11; the disease is non-small cell lung carcinoma.